News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News January 12, 2026
Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.
Firm News December 19, 2025
Gibson Dunn Advised J.P. Morgan Asset Management as Co-Lead Investor in Series L Financing Round of Databricks
Gibson Dunn advised J.P. Morgan Asset Management as co-lead investor in the Series L financing round of Databricks.
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News October 8, 2025
Gibson Dunn Advises XOMA Royalty on Establishing At-The-Market Facilities for the Sale of Shares of Common Stock and Depositary Shares
Gibson Dunn advised XOMA Royalty Corporation on establishing an at-the-market facility for the sale of up to $75 million of shares of its common stock and an at-the-market facility for the sale of up to $50 million of its depositary shares.
Firm News September 19, 2025
Gibson Dunn Advised True Wind Capital in Recapitalization of AIA Contract Documents
Gibson Dunn represented True Wind Capital in the recapitalization of AIA Contract Documents alongside Welsh, Carson, Anderson & Stowe.
Firm News September 4, 2025
Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Licensing and Collaboration Agreement with Novartis
Gibson Dunn is advising Arrowhead Pharmaceuticals on its global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies, as well as for additional collaboration targets utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform
Firm News August 20, 2025
Gibson Dunn Advises Certain Senior Creditors in Recapitalization of Mavenir Systems
Gibson Dunn advised affiliated lenders and noteholders of a special situations fund in connection with the comprehensive recapitalization of Mavenir Systems, Inc., a cloud-native network infrastructure provider
Firm News August 11, 2025
Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics
Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China